Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Daiichi Sankyo
Pharma
Gilead's Trodelvy stumbles in first-line NSCLC
Despite Trodelvy's flop, analysts remain hopeful that Merck's rival TROP2 ADC, sac-TMT, can succeed in the same first-line NSCLC setting.
Angus Liu
Jun 9, 2026 11:14am
AZ, Daiichi's Datroway approved in first-line TNBC
May 22, 2026 11:32am
Merck-Kelun, China deal wisdom, Takeda—Fierce Pharma Asia
May 22, 2026 8:53am
In endometrial cancer, Merck and Kelun score with sac-TMT
May 18, 2026 11:21am
Enhertu secures dual FDA approvals in early breast cancer
May 18, 2026 10:52am
BMS-Hengrui, Takeda layoffs, Daiichi—Fierce Pharma Asia
May 15, 2026 8:30am
